Abstract
MicroRNAs (miRNAs) are approximately 22-nucleotide noncoding RNAs that constitute silencers of target gene expression and have emerged as key regulatory molecules of mammalian cell functions. Aberrant miRNA expression promotes pathologic conditions including hepatocellular carcinoma (HCC) and a variety of precancerous liver diseases, especially chronic hepatitis B and C, and liver cirrhosis. miRNAs may contribute to HCC development by acting as oncogenes or tumor suppressors. Specific alterations of miRNA expression have also been related to clinical features of HCC, such as stage, differentiation, prognosis, and response to adjuvant therapy. miRNA signatures may help define molecular profiles of liver diseases as biomarkers, and allow classification of different stages of cirrhosis and HCC progression. Either miRNAs, or anti-miRNA oligonucleotides (antagomirs) could be used for in vivo modulation of miRNA actions, and thus have significant potential in molecularly targeted therapy.
Keywords: microRNA, hepatocellular carcinoma, liver diseases, noncoding RNAs, silencers, gene expression, oncogenes, tumor suppressors, antagomirs, targeted therapy
Current Pharmaceutical Design
Title:The Expression Patterns and Clinical Significance of microRNAs in Liver Diseases and Hepatocellular Carcinoma
Volume: 19 Issue: 7
Author(s): Jinsheng Guo and Scott L. Friedman
Affiliation:
Keywords: microRNA, hepatocellular carcinoma, liver diseases, noncoding RNAs, silencers, gene expression, oncogenes, tumor suppressors, antagomirs, targeted therapy
Abstract: MicroRNAs (miRNAs) are approximately 22-nucleotide noncoding RNAs that constitute silencers of target gene expression and have emerged as key regulatory molecules of mammalian cell functions. Aberrant miRNA expression promotes pathologic conditions including hepatocellular carcinoma (HCC) and a variety of precancerous liver diseases, especially chronic hepatitis B and C, and liver cirrhosis. miRNAs may contribute to HCC development by acting as oncogenes or tumor suppressors. Specific alterations of miRNA expression have also been related to clinical features of HCC, such as stage, differentiation, prognosis, and response to adjuvant therapy. miRNA signatures may help define molecular profiles of liver diseases as biomarkers, and allow classification of different stages of cirrhosis and HCC progression. Either miRNAs, or anti-miRNA oligonucleotides (antagomirs) could be used for in vivo modulation of miRNA actions, and thus have significant potential in molecularly targeted therapy.
Export Options
About this article
Cite this article as:
Guo Jinsheng and L. Friedman Scott, The Expression Patterns and Clinical Significance of microRNAs in Liver Diseases and Hepatocellular Carcinoma, Current Pharmaceutical Design 2013; 19 (7) . https://dx.doi.org/10.2174/138161213804805667
DOI https://dx.doi.org/10.2174/138161213804805667 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Development of Metal-Based Drugs and Application in Clinical Treatment
The Natural Products Journal Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease
Current Molecular Medicine Anti-Tumor Vaccines in Head and Neck Cancer: Targeting Immune Responses to the Tumor
Current Cancer Drug Targets Editorial [Hot Topic: Recent Advances Into the Molecular Mechanisms and Therapeutic Targeting of Hepatocellular Carcinoma (Guest Editors: Dr. Mei-Sze Chua and Li Wang)]
Anti-Cancer Agents in Medicinal Chemistry 89Zr Radiochemistry for Positron Emission Tomography
Medicinal Chemistry Understanding Autophagy in Cell Death Control
Current Pharmaceutical Design Pomegranate Extract, A Prooxidant with Antiproliferative and Proapoptotic Activities Preferentially Towards Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry STAT Signaling and Cell Function
Current Genomics The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Coagulation and Cancer Therapy: The Potential of Natural Compounds
Current Genomics Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer
Current Cancer Drug Targets Detection of Cancer Cells on a Chip
Current Topics in Medicinal Chemistry Liposome Encapsulated All Trans Retinoic Acid (ATRA) has Enhanced Immunomodulatory and Inflammation Reducing Activities in Mice Model
Anti-Cancer Agents in Medicinal Chemistry The PI3 Kinase Signaling Pathway in Prostate Cancer
Current Cancer Drug Targets Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Molecular and Thermodynamic Studies on DNA Triplex Formed in the Promoter Region of HMGB1 Gene as a Selective Target for Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Current Medicinal Chemistry